These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11189437)

  • 1. New strategies against an old plague: genetically engineered tuberculosis vaccines.
    Dreher D; Kok M; Pechère JC; Nicod LP
    Schweiz Med Wochenschr; 2000 Dec; 130(50):1925-9. PubMed ID: 11189437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoprophylaxis of tuberculosis: an update of emerging trends.
    Singhal N; Bisht D; Joshi B
    Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):97-106. PubMed ID: 20140756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in improved tuberculosis vaccines.
    McMurray DN
    Indian J Pediatr; 2000 Feb; 67(2 Suppl):S58-62. PubMed ID: 11129910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current tuberculosis vaccine development.
    Young DB
    Clin Infect Dis; 2000 Jun; 30 Suppl 3():S254-6. PubMed ID: 10875794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.
    Brodin P; Majlessi L; Brosch R; Smith D; Bancroft G; Clark S; Williams A; Leclerc C; Cole ST
    J Infect Dis; 2004 Jul; 190(1):115-22. PubMed ID: 15195250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis.
    Xing Z; Charters TJ
    Expert Rev Vaccines; 2007 Aug; 6(4):539-46. PubMed ID: 17669008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of novel TB vaccine candidates and their evaluation as DNA vaccines against aerosol challenge.
    Vipond J; Vipond R; Allen-Vercoe E; Clark SO; Hatch GJ; Gooch KE; Bacon J; Hampshire T; Shuttleworth H; Minton NP; Blake K; Williams A; Marsh PD
    Vaccine; 2006 Sep; 24(37-39):6340-50. PubMed ID: 16781800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis: vaccines in the pipeline.
    Ly LH; McMurray DN
    Expert Rev Vaccines; 2008 Jul; 7(5):635-50. PubMed ID: 18564018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant and synthetic peptides to identify Mycobacterium tuberculosis antigens and epitopes of diagnostic and vaccine relevance.
    Mustafa AS
    Tuberculosis (Edinb); 2005; 85(5-6):367-76. PubMed ID: 16253561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Perspectives for new anti-tuberculous vaccines in the post-genomic era].
    García LF; Barrera LF
    Biomedica; 2004 Jun; 24 Supp 1():228-38. PubMed ID: 15495589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a new recombinant BCG which contains mycobacterial antigen ag85B-mpt64(190-198)-mtb8.4 in C57/BL6 mice.
    Qie YQ; Wang JL; Zhu BD; Xu Y; Wang QZ; Chen JZ; Wang HH
    Scand J Immunol; 2008 Feb; 67(2):133-9. PubMed ID: 18201368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of mutant mycobacteria as new vaccines to prevent tuberculosis.
    Hernàndez Pando R; Aguilar LD; Infante E; Cataldi A; Bigi F; Martin C; Gicquel B
    Tuberculosis (Edinb); 2006; 86(3-4):203-10. PubMed ID: 16542875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
    Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
    Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New issues in tuberculosis.
    Kaufmann SH
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii50-ii56. PubMed ID: 15479872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Up-to-date understanding of tuberculosis immunity].
    Mitsuyama M; Akagawa K; Kobayashi K; Sugawara I; Kawakami K; Yamamoto S; Okada Z
    Kekkaku; 2003 Jan; 78(1):51-5. PubMed ID: 12683337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational design of vaccines against tuberculosis directed by basic immunology.
    Reece ST; Kaufmann SH
    Int J Med Microbiol; 2008 Jan; 298(1-2):143-50. PubMed ID: 17702652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in the development of new vaccines against tuberculosis.
    Orme IM
    Int J Tuberc Lung Dis; 1997 Apr; 1(2):95-100. PubMed ID: 9441089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.